Synthetic Or Structurally-modified Peptidoglycan Or Mucopolysaccharide Or Fragment Thereof (e.g., Derivative Of N-acetyl-muramyl-l-alanyl-d-glutamic Or Fragment Thereof (e.g., Derivative Of N-acetyl-muramyl-l-alanyl-d- Acid, Etc.) Glutamic Acid, Etc.) Patents (Class 424/279.1)
-
Patent number: 11124815Abstract: Embodiments of the disclosure provide for unique lipooligosaccharide/lipid A-based mimetics for use as adjuvants. Methods of generating lipooligosaccharide/lipid A-based mimetics are provided that utilize recombinantly engineered bacteria to produce the mimetics, including, for example, addition of one or more particular enzymes such as acyltransferases, deacylases, phosphatases, or glycosyltransferases.Type: GrantFiled: June 4, 2019Date of Patent: September 21, 2021Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, UNIVERSITY OF WASHINGTONInventors: Robert K. Ernst, Mark Pelletier, Adeline Hajjar
-
Patent number: 10583175Abstract: A composition in aqueous solution includes insulin and at least one substituted anionic compound chosen from substituted anionic compounds consisting of a backbone formed from a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycoside bonds, the saccharide units being chosen from the group consisting of hexoses, in cyclic form or in open reduced form, said compound comprising partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. A pharmaceutical formulation including the composition is also set forth.Type: GrantFiled: May 31, 2017Date of Patent: March 10, 2020Assignee: ADOCIAInventors: Olivier Soula, Gerard Soula, Emmanuel Dauty, Richard Charvet
-
Patent number: 9550164Abstract: The present disclosure relates to an apparatus and process for forming medical devices from an injectable composition. The apparatus includes a supply assembly configured to maintain and selective dispense a first precursor and a second precursor, a mixing assembly configured to mix the first and second precursors, and at least one catalyzing element including a transition metal ion to aid in the polymerization of the first and second precursors. The process includes dispensing a volume of the first precursor and a volume of the second precursor into a mixing assembly and mixing the first and second precursors. The first and second precursors each possess a core and at least one functional group known to have click reactivity with each other. The mixed precursors are contacted with a transition metal catalyst to produce a flowable composition for use as a medical device.Type: GrantFiled: April 22, 2015Date of Patent: January 24, 2017Assignee: Sofradim ProductionInventors: Sébastien Ladet, Philippe Gravagna
-
Publication number: 20150079155Abstract: This invention concerns a liposome comprising lipids and at least one active ingredient, wherein at least one of the lipids is a cationic lipid; said liposome exhibiting a net positive charge at physiological conditions at which said liposome preferentially adheres to monocytes in freshly drawn blood when compared to adherence to granulocytes, T-lymphocytes, B-lymphocytes and/or NK cells in freshly drawn blood, to a lipid-based pharmaceutical composition comprising said liposomes and their use in monocytic associated prophylaxis, treatment or amelioration of a condition such as cancer, an infectious disease, an inflammatory disease, an autoimmune disease or allergy.Type: ApplicationFiled: March 14, 2013Publication date: March 19, 2015Inventors: Simon Skjøde Jensen, Thomas Lars Andresen, Jonas Rosager Henriksen, Pia Thermann Johansen
-
Publication number: 20150056254Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.Type: ApplicationFiled: February 7, 2013Publication date: February 26, 2015Applicant: PHI BioMed Co., Ltd.Inventors: Sei Kwang Hahn, Eung-Sam Kim, Jeonga Yang, Hyemin Kim, Kwan Yong Choi, Ji Hye Shin, Jung-Hee Kwon
-
Patent number: 8945604Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.Type: GrantFiled: September 20, 2013Date of Patent: February 3, 2015Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Patent number: 8936793Abstract: Archaeal lipid adjuvants are synthesized by chemically coupling various carbohydrates or anionic polar groups to the free hydroxyl(s) of archaeal lipid cores. Chemically stable lipid cores such as saturated archaeol and caldarchaeol are obtained from appropriate Archaea. Archaeosome lipid vesicles are formulated from the synthetic lipids selected to serve as antigen carriers that target antigen-presenting cells and promote an appropriate immune response to the antigen.Type: GrantFiled: March 30, 2007Date of Patent: January 20, 2015Assignee: National Research Council of CanadaInventors: Dennis Sprott, Dennis M. Whitfield, Lakshmi Krishnan
-
Publication number: 20150004130Abstract: The invention relates to a nutritional composition comprising (a) at least 18 en % of proteinaceous matter; (b) at least 12 wt % of leucine, based on total proteinaceous matter; (c) a lipid fraction comprising at least a ?-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid; (d) an immune modulator; for improving the immune function in a mammal, preferably a human.Type: ApplicationFiled: September 15, 2014Publication date: January 1, 2015Inventors: Joyce FABER, Adrianus Lambertus Bertholdus VAN HELVOORT, Klaske VAN NORREN, Arjan Paul VOS, Robert Johan Joseph HAGEMAN, Cornelus Johannes Petrus VAN LIMPT
-
Patent number: 8889134Abstract: The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof.Type: GrantFiled: January 22, 2013Date of Patent: November 18, 2014Assignee: Agency for Science, Technology and ResearchInventors: Yue Wang, Xiao-Li Xu, Raymond Teck Ho Lee
-
Patent number: 8822418Abstract: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.Type: GrantFiled: May 24, 2010Date of Patent: September 2, 2014Assignee: Brown UniversityInventors: Justin R. Fallon, Michael Rafii, Mark A. Bowe, Beth McKechnie, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Publication number: 20140170183Abstract: The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.Type: ApplicationFiled: November 27, 2013Publication date: June 19, 2014Applicant: The Regents of the University of CaliforniaInventors: Carolyn R. Bertozzi, Mary Sloan Siegrist Palmore, John C. Jewett, Chelsea G. Gordon, Peyton Shieh
-
Patent number: 8709448Abstract: The present invention is concerned with novel immunostimulant microparticle compositions and their use as anti-infective agents in the treatment of bacterial and viral infections.Type: GrantFiled: April 1, 2009Date of Patent: April 29, 2014Assignee: Innate Immunotherapeutics Ltd.Inventors: Frank B Gelder, Gillian Alison Webster
-
Publication number: 20140105935Abstract: Described herein are compositions that include isolated opsonized soluble ?-glucan, methods of making those compositions and methods of using those compositions.Type: ApplicationFiled: June 1, 2012Publication date: April 17, 2014Inventors: Nandita Bose, Anissa S.H. Chan
-
Publication number: 20140079772Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.Type: ApplicationFiled: September 16, 2013Publication date: March 20, 2014Inventor: Young Hee Ko
-
Patent number: 8663654Abstract: The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a vaccine for inducing active immunity to infections caused by Staphylococcus aureus, S. epidermidis, other related coagulase-negative staphylococci and organisms carrying the ica (intracellular adhesin) locus, and to the use of antibodies directed to PS/A for inducing passive immunity to the same class of infections.Type: GrantFiled: December 22, 2006Date of Patent: March 4, 2014Assignee: The Brigham and Women's Hospital, Inc.Inventors: Gerald B. Pier, Julia Wang, David McKenney
-
Patent number: 8609114Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: GrantFiled: August 30, 2012Date of Patent: December 17, 2013Assignee: Infectious Diesease Research InstituteInventor: Steven G. Reed
-
Patent number: 8563028Abstract: The present invention provides an ophthalmic device, and method of use thereof, for an individual wearing an ophthalmic lens to increase ocular surface boundary lubrication. The invention device comprises an ophthalmic lens and a sacrificial mechanism disposed on the ophthalmic lens, wherein the sacrificial mechanism comprises a plurality of surface bound receptors, such as PRG4, hyaluronic acid, and DNA aptamers, that reversibly bound to a lubricating composition comprising a gel forming agent, a surfactant, or a combination thereof, effectively inhibiting or preventing protein and lipid adsorption on the surface of the lens, and mitigate shear stress and reduce the friction between the lens and the ocular surface of the individual in need.Type: GrantFiled: November 5, 2010Date of Patent: October 22, 2013Assignees: The Regents of the University of California, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
-
Publication number: 20130236496Abstract: The present invention relates to the use of leukotriene B4 to enhance the response of Toll-like receptor (TLR), RIG-I-like receptor (RLR), and NOD-like receptor (NLR) when stimulated simultaneously with respective proper ligands. The use in combination of LTB4 with those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders.Type: ApplicationFiled: June 20, 2011Publication date: September 12, 2013Applicant: UNIVERSITE DE LAVALInventors: Jean Gosselin, Eric Gaudreault
-
Patent number: 8512752Abstract: Crosslinked derivatives of polycarboxylated polysaccharides are described, wherein at least one of the polysaccharide chains consists of hyaluronic acid or a derivative thereof, crosslinked by means of reactions of the “click chemistry” type and their use in the field of viscosupplementation, plastic surgery, oncologic and reconstructive surgery and also as matrices for controlled release systems of biologically and/or pharmacologically active molecules and/or macromolecules.Type: GrantFiled: September 5, 2007Date of Patent: August 20, 2013Assignee: Fidia Farmaceutici S.p.A.Inventors: Di Meo Chiara, Devis Galesso, Ada Mascolo, Fabiana Crescenzi, Alberta Crescenzi, Flavia Crescenzi, Fulvia Crescenzi, Laura Crescenzi, Vittoria Crescenzi
-
Patent number: 8470343Abstract: The present invention relates generally to a method of eliciting or otherwise inducing an effective immune response to a micro-organism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as “GPI”) inositolglycan domain or its derivatives. Even more particularly, the present invention contemplates an immunogenic composition comprising the Plasmodium falciparum GPI inositolglycan domain or its derivatives. The present invention is useful, inter alia, as a prophylactic and/or therapeutic treatment for disease conditions such as, for example, infection by parasites and in particular infection by Plasmodium species.Type: GrantFiled: October 7, 2011Date of Patent: June 25, 2013Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventor: Louis Schofield
-
Patent number: 8383110Abstract: The invention relates to modulation of fungal morphology between yeast-to-hyphal growth transition by controlling muramyl-L-alanine concentration and uses thereof.Type: GrantFiled: August 21, 2007Date of Patent: February 26, 2013Assignee: Agency for Science, Technology and ResearchInventors: Yue Wang, Xiao-Li Xu, Teck Ho Raymond Lee
-
Publication number: 20120164174Abstract: The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies.Type: ApplicationFiled: June 25, 2010Publication date: June 28, 2012Applicants: BIOLEADERS CORPORATION, KOOKMIN UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION, THE INDUSTRY AND ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Moon-Hee Sung, Haryoung Poo, Chul Joong Kim, Young-Ki Choi, Yong Taík Lim, Dong Jin Jeong, Sang-Mu Shim
-
Patent number: 8202523Abstract: The invention provides various high mannose glycosylated polypeptides that are useful in a vaccine formulations. The invention also provides methods for making such glycosylated polypeptides and its uses in eliciting HIV-neutralizing antibodies.Type: GrantFiled: September 22, 2006Date of Patent: June 19, 2012Assignee: ProSci, Inc.Inventors: Yu Geng, Robert James Luallen
-
Patent number: 8187614Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.Type: GrantFiled: September 3, 2010Date of Patent: May 29, 2012Assignee: Legere Pharmaceuticals, Ltd.Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
-
Patent number: 8138154Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: July 6, 2009Date of Patent: March 20, 2012Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 8129518Abstract: Provided are synthetic polysaccharide antigens (SPAs) with anti-inflammatory or inflammatory immunomodulatory properties, depending on their structure. Also provided are compositions comprising these SPAs, and methods of using these SPAs and compositions to either prevent or treat inflammatory pathologies, or diseases or conditions susceptible to treatment with inflammatory immunomodulators, by using appropriate SPAs.Type: GrantFiled: September 15, 2004Date of Patent: March 6, 2012Assignee: Eli Lilly and CompanyInventors: Larry Chris Blaszczak, John Astor Cleveland, Jr., Kathleen Ann Taylor, Neil Thomas Blackburn, Angelika Regina Kraft, Charles Ellis Cohen
-
Publication number: 20120039849Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.Type: ApplicationFiled: August 17, 2011Publication date: February 16, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Alex Aronov, Upul Keerthi Bandarage, Kevin Michael Cottrell, Robert J. Davies, Elaine B. Krueger, Mark Willem Ledeboer, Brian Ledford, Arnaud Le Tiran, David Messersmith, Tiansheng Wang, Jinwang Xu, Yusheng Liao
-
Publication number: 20120021043Abstract: The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.Type: ApplicationFiled: January 28, 2009Publication date: January 26, 2012Applicant: CureVac GmbHÛInventors: Thomas Kramps, Sohnke Voss, Jochen Probst, Ingmar Hoerr
-
Patent number: 7883876Abstract: Provided are methods for recombinant production of an O-acetyltransferase and methods for acetylating capsular polysaccharides, especially those of a Serogroup A Neisseria meningitidis using the recombinant O-acetyltransferase, and immunogenic compositions comprising the acetylated capsular polysaccharide.Type: GrantFiled: November 20, 2007Date of Patent: February 8, 2011Inventors: David S. Stephens, Seshu K. Gudlavalleti, Yih-Ling Tzeng, Anup K. Datta, Russell W. Carlson
-
Publication number: 20110002978Abstract: Conjugates for use in an enzyme prodrug cancer therapy treatment are provided.Type: ApplicationFiled: March 10, 2010Publication date: January 6, 2011Inventor: ROGER G. HARRISON
-
Patent number: 7816322Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: February 22, 2008Date of Patent: October 19, 2010Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 7795235Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: December 17, 2008Date of Patent: September 14, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Patent number: 7790672Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.Type: GrantFiled: April 28, 2006Date of Patent: September 7, 2010Assignee: Legere Pharmaceuticals, Inc.Inventors: Howard C. Krivan, Richard C. Potter, Michael J. Oldham
-
Patent number: 7790189Abstract: Disclosed is a new type of immunostimulating agent including an immunostimulating oligonucleotide complexed with a carrier which is safe and has a high transfection effect. The carrier complexed with the immunostimulating oligonucleotide to form the immunostimulating agent is a polysaccharide having ?-1,3-bonds (preferably ?-1,3-glucan such as schizophyllan). A preferred example of the immunostimulating oligonucleotide is one containing an unmethylated CpG motif. The polysaccharide for use is preferably modified with nucleic acid-binding functional group and/or cell membrane-affinitive functional group.Type: GrantFiled: May 13, 2004Date of Patent: September 7, 2010Assignees: Mitsui Sugar Co., Ltd., Japan Science and Technology AgencyInventors: Masami Mizu, Seiji Shinkai, Kazuo Sakurai, Kazuya Koumoto, Munenori Numata, Takahiro Matsumoto
-
Patent number: 7612038Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: February 20, 2002Date of Patent: November 3, 2009Assignee: Brown UniversityInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
-
Patent number: 7585847Abstract: The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.Type: GrantFiled: February 2, 2001Date of Patent: September 8, 2009Assignee: Coley Pharmaceutical Group, Inc.Inventors: Robert L. Bratzler, Deanna M. Petersen, Yves Fouron
-
Publication number: 20090214598Abstract: The present invention provides a pro-inflammatory synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which a first epitope and a second epitope are each covalently attached. The first epitope comprises one or more than one generic T helper peptide sequence, and the second epitope comprises one or more than one target epitope. The first and second epitopes are present in one or more copies each within the SPA. Each target epitope is a peptide sequence or a carbohydrate moiety, and is an immunogen to CD8+ T cells or B cells. The present invention also provides a suppressive synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2-targeting synthetic peptidoglycan (PGN) moiety onto which one or more than one target epitope is covalently attached.Type: ApplicationFiled: April 19, 2006Publication date: August 27, 2009Applicant: Eli Lilly and CompanyInventor: Larry Chris Blaszczak
-
Patent number: 7541039Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.Type: GrantFiled: December 9, 2005Date of Patent: June 2, 2009Assignee: Applied NanoSystems, B.V.Inventors: Cornelis Johannes Leenhouts, Ranjan Ramasamy, Anton Steen, Jan Kok, Girbe Buist, Oscar Paul Kuipers
-
Patent number: 7531181Abstract: The present invention provides multi-antigenic constructs comprising one or more carbohydrate antigens having the formula: wherein R1, R2A, R2B, R3, R4, W1, W2 and W3 are as defined herein; and additionally provides compositions thereof, and methods for their use in the treatment and/or prevention of HIV infection, and methods for inducing HIV-specific antibodies in a subject, comprising administering to a subject in need thereof, an effective amount of any of the inventive compounds as disclosed herein, either in conjugated form or unconjugated and in combination with a suitable immunogenic carrier. In another aspect, the invention provides an antibody or antibody fragment which binds specifically to a gp120 glycan or glycopeptide of the invention.Type: GrantFiled: June 3, 2005Date of Patent: May 12, 2009Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Vadim Dudkin, Xudong Geng, Mihirbaran Mandal, Isaac Kraus
-
Patent number: 7351435Abstract: The present invention relates to a vaccine comprising deglycosylated ricin toxin A-chain and method for making and using the composition.Type: GrantFiled: September 24, 2001Date of Patent: April 1, 2008Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Robert W. Wannemacher, John F. Hewetson
-
Patent number: 7335637Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.Type: GrantFiled: June 14, 2004Date of Patent: February 26, 2008Assignee: Brown University Research FoundationInventors: Justin R. Fallon, Beth McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Raymond Ferri
-
Patent number: 7326681Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: GrantFiled: September 30, 2005Date of Patent: February 5, 2008Assignee: GlycoFi, Inc.Inventor: Tillman U. Gerngross
-
Patent number: 7083798Abstract: The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the effects of insulin-dependant diabetes mellitus (IDDM) by administering a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source.Type: GrantFiled: November 13, 1997Date of Patent: August 1, 2006Assignee: Centenary Institute of Cancer Medicine and Cell BiologyInventor: Alan George Baxter
-
Patent number: 7067639Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.Type: GrantFiled: December 16, 2002Date of Patent: June 27, 2006Assignee: Applied Nanosystems B.V.Inventors: Cornelis J. Leenhouts, Ranjan Ramasamy, Anton Steen, Jan Kok, Girbe Buist, Oscar P. Kuipers
-
Patent number: 7037893Abstract: Glycopeptides capable of identifying multiple sclerosis antibodies, and therefore useful as diagnostic tools or for the treatment of said pathology are described.Type: GrantFiled: June 19, 2002Date of Patent: May 2, 2006Assignee: Universita' Degli Studi Di FirenzeInventors: Anna Maria Papini, Mario Chelli, Paolo Rovero, Francesco Lolli
-
Patent number: 7001907Abstract: This invention relates to peptide-containing ?-ketoamide inhibitors of cysteine and serine proteases, methods for making these compounds, and methods for using the same.Type: GrantFiled: October 14, 2003Date of Patent: February 21, 2006Assignee: Cephaon, Inc.Inventors: Sankar Chatterjee, John P. Mallamo, Ron Bihovsky, Gregory J. Wells
-
Patent number: 6960452Abstract: Disclosed are materials that may be used in the design of improved devices and wound treatment platforms though covalent and/or non-covalent attachment of bioactive proteins. The proteins comprise any variety of cell growth and/or healing promoting proteins, such as growth factor. The incorporation of these whole proteins may be designed to provide controlled release thereof in a biological system through further use of enzyme degradation sites. Heparin-binding protein or fusion proteins synthesized to contain a heparin-binding domain are two mechanisms that may be used in providing these properties to a matrix, such as a fibrinogen matrix. The proteins will be used to provide enhanced healing in various tissues including vasculature, skin, nerve, and liver. The materials disclosed will be used to enhance would?? Healing and other generative processes by engineering the fibrin gel to contain appropriate proteins with specifically designed release and/or degradation characteristics.Type: GrantFiled: March 2, 2001Date of Patent: November 1, 2005Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jeffrey A. Hubbell, Jason C. Schense, Shelly E. Sakiyama
-
Patent number: 6932972Abstract: Novel combined vaccine composition preferentially for administration to adolescents are provided, comprising a hepatitis B viral antigen and a herpes simplex viral antigen and optionally in addition one or more of the following: an EBV antigen, a hepatitis A antigen or inactivated attenuated virus, an HPV antigen, a V2V antigen, a HCMV antigen, a Toxoplasma gondii antigen. The vaccine compositions are formulated with an adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21.Type: GrantFiled: August 23, 2002Date of Patent: August 23, 2005Assignee: SmithKline Beecham Biologicals S.A.Inventors: Jean Stephenne, Martine Anne Cecile Wettendorff
-
Patent number: 6921537Abstract: Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis. LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.Type: GrantFiled: March 5, 2002Date of Patent: July 26, 2005Assignee: WyethInventor: Gary W. Zlotnick
-
Patent number: 6903100Abstract: The present invention is directed to the treatment of multiple sclerosis by periodically administering a high dose of methotrexate at a level sufficiently high to cross the blood brain barrier. The methotrexate administration is accompanied by leucovorin rescue of the periphery. The high dose methotrexate is preferably administered at 1 to 4 month intervals. The periodic high dose methotrexate treatment may be used in conjunction with interim treatments using a therapeutic agent that is effective in treating MS, but does not cross the BBB in cytotoxic amounts. It is contemplated that the method of the present invention may be employed to treat other non-infectious, non-neoplastic inflammatory conditions of the CNS.Type: GrantFiled: April 24, 2002Date of Patent: June 7, 2005Assignee: MidAmerica Neuroscience Research FoundationInventor: Vernon D. Rowe